EAACI Congress 2023
BackTargeting eosinophilic esophagitis
Friday 09 Jun, 12:00 PM -
13:00 PM CEST
Hall Y 03+04
ORAL Session
12:00
Dupilumab improves histologic, symptomatic, and endoscopic outcomes in eosinophilic esophagitis, regardless of history of food allergy or food elimination diets
12:12
Dupilumab improves type 2 comorbidity outcomes in patients with eosinophilic esophagitis and history of comorbid disease at baseline: Results from Parts A and B of LIBERTY-EoE-TREET
12:24
Effect of dupilumab treatment on inflammatory type 2 biomarkers in patients with eosinophilic esophagitis: Part B of LIBERTY-EoE-TREET
12:36
Granzyme B is elevated in esophageal biopsies in Pediatric Eosinophilic Esophagitis
12:48
High exposure to advanced glycation end-products could facilitate the occurrence of pediatric Eosinophilic Esophagitis
